Literature DB >> 9232642

The crystal structure of human alpha-thrombin complexed with LY178550, a nonpeptidyl, active site-directed inhibitor.

N Y Chirgadze1, D J Sall, V J Klimkowski, D K Clawson, S L Briggs, R Hermann, G F Smith, D S Gifford-Moore, J P Wery.   

Abstract

The crystal structure of human alpha-thrombin in complex with LY178550, a nonpeptidyl, active site-directed inhibitor, has been solved to 2.07 A resolution by the method of X-ray crystallography. The final model of the complex has a crystallographic R-value of 21.5% (Rfree = 23.1%) with 0.014 A and 2.4 degrees standard deviation from ideal bond lengths and angles, respectively. Well-defined electron density was observed for the inhibitor in the active site. The inhibitor binds to the active site in an L-shaped manner, mimicking the bound conformation of the tripeptide arginal series of thrombin inhibitors (Chirgadze NY et al., 1992, American Crystallographic Association Meeting 20: 116 [Abstr. PB311]). The basic amidine of LY178550 forms a salt bridge with Asp 189 within the specificity pocket, while the 4-benzylpiperidine side chain engages in a number of hydrophobic interactions at the S2 and S3 binding sites. The inhibitor does not interact in any fashion with the active site sequence Ser 214-Gly 216, as occurs with many of the inhibitors studied previously. The indole N-H of the inhibitor forms a hydrogen bond to the gamma-oxygen of the catalytic serine (Ser 195).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9232642      PMCID: PMC2143747          DOI: 10.1002/pro.5560060705

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  10 in total

1.  Structure of the hirugen and hirulog 1 complexes of alpha-thrombin.

Authors:  E Skrzypczak-Jankun; V E Carperos; K G Ravichandran; A Tulinsky; M Westbrook; J M Maraganore
Journal:  J Mol Biol       Date:  1991-10-20       Impact factor: 5.469

2.  Crystallographic determination of the structures of human alpha-thrombin complexed with BMS-186282 and BMS-189090.

Authors:  M F Malley; L Tabernero; C Y Chang; S L Ohringer; D G Roberts; J Das; J S Sack
Journal:  Protein Sci       Date:  1996-02       Impact factor: 6.725

3.  Correlation of the in vivo anticoagulant, antithrombotic, and antimetastatic efficacy of warfarin in the rat.

Authors:  G F Smith; B L Neubauer; J L Sundboom; K L Best; R L Goode; L R Tanzer; R L Merriman; J D Frank; R G Herrmann
Journal:  Thromb Res       Date:  1988-04-01       Impact factor: 3.944

4.  LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions.

Authors:  A C Wallace; R A Laskowski; J M Thornton
Journal:  Protein Eng       Date:  1995-02

5.  Satisfying hydrogen bonding potential in proteins.

Authors:  I K McDonald; J M Thornton
Journal:  J Mol Biol       Date:  1994-05-20       Impact factor: 5.469

Review 6.  Computational methods to predict binding free energy in ligand-receptor complexes.

Authors:  M A Murcko
Journal:  J Med Chem       Date:  1995-12-22       Impact factor: 7.446

7.  Amidino-substituted aromatic heterocycles as probes of the specificity pocket of trypsin-like proteases.

Authors:  J D Geratz; F M Stevens; K L Polakoski; R F Parrish; R R Tidwell
Journal:  Arch Biochem Biophys       Date:  1979-10-15       Impact factor: 4.013

8.  Comparative activity of thrombin on substituted arginine and lysine esters.

Authors:  S Sherry; N Alkjaersig; A P Fletcher
Journal:  Am J Physiol       Date:  1965-09

9.  A family of arginal thrombin inhibitors related to efegatran.

Authors:  G F Smith; R T Shuman; T J Craft; D S Gifford; K D Kurz; N D Jones; N Chirgadze; R B Hermann; W J Coffman; G E Sandusky; E Roberts; C V Jackson
Journal:  Semin Thromb Hemost       Date:  1996       Impact factor: 4.180

10.  Highly selective tripeptide thrombin inhibitors.

Authors:  R T Shuman; R B Rothenberger; C S Campbell; G F Smith; D S Gifford-Moore; P D Gesellchen
Journal:  J Med Chem       Date:  1993-02-05       Impact factor: 7.446

  10 in total
  3 in total

1.  The crystal structures of human alpha-thrombin complexed with active site-directed diamino benzo[b]thiophene derivatives: a binding mode for a structurally novel class of inhibitors.

Authors:  N Y Chirgadze; D J Sall; S L Briggs; D K Clawson; M Zhang; G F Smith; R W Schevitz
Journal:  Protein Sci       Date:  2000-01       Impact factor: 6.725

2.  Identification and characterization of small-molecule inhibitors of hepsin.

Authors:  John R Chevillet; Gemma J Park; Antonio Bedalov; Julian A Simon; Valeri I Vasioukhin
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

3.  GeauxDock: Accelerating Structure-Based Virtual Screening with Heterogeneous Computing.

Authors:  Ye Fang; Yun Ding; Wei P Feinstein; David M Koppelman; Juana Moreno; Mark Jarrell; J Ramanujam; Michal Brylinski
Journal:  PLoS One       Date:  2016-07-15       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.